MD, Department of Pediatrics/Division of Endocrinology, A5902, Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, Washington 98105.
J Clin Endocrinol Metab. 2013 Oct;98(10):4055-62. doi: 10.1210/jc.2013-1279. Epub 2013 Jun 14.
Our study aims were to determine the frequency of MODY mutations (HNF1A, HNF4A, glucokinase) in a diverse population of youth with diabetes and to assess how well clinical features identify youth with maturity-onset diabetes of the young (MODY).
The SEARCH for Diabetes in Youth study is a US multicenter, population-based study of youth with diabetes diagnosed at age younger than 20 years. We sequenced genomic DNA for mutations in the HNF1A, HNF4A, and glucokinase genes in 586 participants enrolled in SEARCH between 2001 and 2006. Selection criteria included diabetes autoantibody negativity and fasting C-peptide levels of 0.8 ng/mL or greater.
We identified a mutation in one of three MODY genes in 47 participants, or 8.0% of the tested sample, for a prevalence of at least 1.2% in the pediatric diabetes population. Of these, only 3 had a clinical diagnosis of MODY, and the majority was treated with insulin. Compared with the MODY-negative group, MODY-positive participants had lower FCP levels (2.2 ± 1.4 vs 3.2 ± 2.1 ng/mL, P < .01) and fewer type 2 diabetes-like metabolic features. Parental history of diabetes did not significantly differ between the 2 groups.
CONCLUSIONS/INTERPRETATION: In this systematic study of MODY in a large pediatric US diabetes cohort, unselected by referral pattern or family history, MODY was usually misdiagnosed and incorrectly treated with insulin. Although many type 2 diabetes-like metabolic features were less common in the mutation-positive group, no single characteristic identified all patients with mutations. Clinicians should be alert to the possibility of MODY diagnosis, particularly in antibody-negative youth with diabetes.
我们的研究旨在确定 MODY 突变(HNF1A、HNF4A、葡萄糖激酶)在不同人群中糖尿病患儿中的发生频率,并评估临床特征在多大程度上可识别青少年起病的成年型糖尿病(MODY)。
SEATCH 糖尿病研究是一项美国多中心、基于人群的研究,纳入了年龄小于 20 岁确诊的糖尿病患儿。我们对 2001 年至 2006 年间入组 SEATCH 的 586 名参与者的 HNF1A、HNF4A 和葡萄糖激酶基因进行了基因突变测序。选择标准包括糖尿病自身抗体阴性和空腹 C 肽水平大于等于 0.8ng/ml。
我们在 47 名参与者(占检测样本的 8.0%)中发现了 3 个 MODY 基因中的一个突变,该突变在儿科糖尿病患者中的患病率至少为 1.2%。其中,只有 3 人被诊断为 MODY,大多数人接受胰岛素治疗。与 MODY 阴性组相比,MODY 阳性组的 FCP 水平较低(2.2±1.4 对 3.2±2.1ng/ml,P<0.01),且较少出现 2 型糖尿病样代谢特征。两组间父母糖尿病史无显著差异。
结论/解释:在这项对美国大型儿科糖尿病队列中 MODY 的系统研究中,未根据转诊模式或家族史选择病例,MODY 通常被误诊,并错误地用胰岛素治疗。虽然在突变阳性组中,许多 2 型糖尿病样代谢特征较少见,但没有任何单一特征能识别所有突变患者。临床医生应警惕 MODY 诊断的可能性,尤其是在糖尿病抗体阴性的青少年中。